SEARCH

SEARCH BY CITATION

References

  • 1
    Smith RE. The Clinical and economic burden of anemia. American Journal of Managed Care 2010; 16: S5966.
  • 2
    Dowling TC. Prevalence, etiology, and consequences of anemia and clinical and economic benefits of anemia correction in patients with chronic kidney disease: an overview. American Journal of Health-System Pharmacy 2007; 64(13 Suppl 8): S3S7.
  • 3
    Go AS, Yang JG, Ackerson LM, et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: the Anemia in Chronic Heart Failure:Outcomes and Resource Utilization (ANCHOR) Study. Circulation 2006; 113: 271323.
  • 4
    Bansal N, Tighiouart H, Weiner D, et al. Anemia as a risk factor for kidney function decline in individuals with heart failure. American Journal of Cardiology 2007; 99(8): 113742.
  • 5
    Tong PC, Kong AP, So WY, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. Diabetes Care 2006; 29(11): 243944.
  • 6
    Kovesdy CP, Trivedi BK, Kalantar-Zadeh K, Anderson JE. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. Kidney International 2006; 69: 5604.
  • 7
    Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Annals of Internal Medicine 2003; 139: 13747.
  • 8
    Landon BE, Normand SL, Blumenthal D, Daley J. Physician clinical performance assessment: prospects and barriers. Journal of the American Medical Association 2003; 290(9): 11839.
  • 9
    U.S. Preventive Services Task Force. Methods and Background. Agency for Healthcare Research and Quality. 2008. Available at URL: http://www.uspreventiveservicestaskforce.org/uspstf08/methods/procfig3.htm
  • 10
    Norris SL, Kansagara D, Bougatsos C, Fu RW. Screening adults for type 2 diabetes: a review of the evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine 2008; 148: 85568.
  • 11
    National Collaborating Centre for Chronic Conditions. Diagnostic evaluation and assessment of anaemia. In: Anaemia Management in Chronic Kidney Disease: National Clinical Guideline for Management in Adults and Children. London : Royal College of Physicians, 2006: 317.
  • 12
    Eborall HC, Griffin SJ, Prevost AT, et al. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. British Medical Journal 2007; 335: 486493.
  • 13
    Sheridan S, Pignone M, Donahue K. Screening for high blood pressure: a review of the evidence for the U.S. Preventive Services Task Force. American Journal of Preventive Medicine 2003; 25: 1518.
  • 14
    Stolk RP. Screening for diabetes. British Medical Journal 2007; 335: 4578.
  • 15
    Revicki DA, Brown RE, Feeny DH, et al. Health-related quality of life associated with recombinant erythropoietin therapy for predialysis chronic renal disease patients. American Journal of Kidney Diseases 1995; 25: 54854.
  • 16
    Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. American Journal of Kidney Diseases 2008; 52(5): 897906. Epub 2008 Oct 8.
  • 17
    Singh AK, Szczech L, Tang KL, et al. CHOIR Investigators: correction of anemia with epoetin alfa in chronic kidney disease. New England Journal of Medicine 2006; 355: 208598.
  • 18
    Drueke TB, Locatelli F, Clyne N, et al. CREATE Investigators: normalization of hemoglobin level in patients with chronic kidney disease and anemia. New England Journal of Medicine 2006; 355: 207184.
  • 19
    Pfeffer MA, Burdmann EA, Chen CY, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. New England Journal of Medicine 2009; 361: 201932.
  • 20
    Boada JN, Boada C, García-Sáiz M, García M, Fernández E, Gómez E. Net efficacy adjusted for risk (NEAR): a simple procedure for measuring risk: benefit balance. PLoS One 2008; 3(10): e3580. Epub 2008 Oct 31.